Renascience Inc. (TYO:4889)
Japan · Delayed Price · Currency is JPY 1,333.00
+24.00 (1.83%)
Aug 27, 2026, 12:45 PM JST
Renascience Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 68 | 68 | 132 | 194 | 100 | 139 | |
Revenue Growth | -33.33% | -48.48% | -31.96% | 94.00% | -28.06% | -33.49% |
Cost of Revenue | 4 | 4 | 4 | 29 | - | 59 |
Gross Profit | 64 | 64 | 128 | 165 | 100 | 80 |
Selling, General & Admin | 177 | 197 | 159 | 167 | 185 | 193 |
Research & Development | 201 | 201 | 132 | 236 | 235 | 82 |
Other Operating Expenses | 23 | 23 | 16 | 13 | 13 | 13 |
Operating Expenses | 401 | 421 | 307 | 417 | 434 | 291 |
Operating Income | -337 | -357 | -179 | -252 | -334 | -211 |
Interest Expense | - | - | - | - | - | -5 |
Interest & Investment Income | 3 | 3 | - | - | - | - |
Currency Exchange Gain (Loss) | - | -1 | -1 | - | - | - |
Other Non Operating Income (Expenses) | 18 | 55 | 1 | -1 | - | -26 |
EBT Excluding Unusual Items | -316 | -300 | -179 | -253 | -334 | -242 |
Asset Writedown | - | - | -1 | -4 | - | -11 |
Other Unusual Items | - | - | 323 | - | - | - |
Pretax Income | -316 | -300 | 143 | -257 | -334 | -253 |
Income Tax Expense | 1 | 1 | 30 | 1 | 1 | 1 |
Net Income | -317 | -301 | 113 | -258 | -335 | -254 |
Net Income to Common | -317 | -301 | 113 | -258 | -335 | -254 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 11 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 11 |
Shares Change | 3.40% | 1.31% | - | - | 11.61% | 15.99% |
EPS (Basic) | -24.12 | -23.37 | 8.89 | -20.30 | -26.35 | -22.30 |
EPS (Diluted) | -24.12 | -23.37 | 8.89 | -20.30 | -26.35 | -22.30 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -291 | -176 | -231 | -286 | -231 |
Free Cash Flow Per Share | - | -22.60 | -13.85 | -18.17 | -22.50 | -20.28 |
Gross Margin | 94.12% | 94.12% | 96.97% | 85.05% | 100.00% | 57.55% |
Operating Margin | -495.59% | -525.00% | -135.61% | -129.90% | -334.00% | -151.80% |
Profit Margin | -466.18% | -442.65% | 85.61% | -132.99% | -335.00% | -182.73% |
Free Cash Flow Margin | - | -427.94% | -133.33% | -119.07% | -286.00% | -166.19% |
EBITDA | - | - | -178 | -251 | -333 | -208 |
EBITDA Margin | - | - | -134.85% | -129.38% | - | -149.64% |
D&A For EBITDA | - | - | 1 | 1 | 1 | 3 |
EBIT | -337 | -357 | -179 | -252 | -334 | -211 |
EBIT Margin | - | - | -135.61% | -129.90% | - | -151.80% |
Effective Tax Rate | - | - | 20.98% | - | - | - |